Figure 12: Effectiveness of the heterospecific tetravalent antibodies to anchor the human induced pluripotent stem cells to the cardiac muscle sarcomeres (hiPSCs arc) was measured by x-ray energy dispersive spectroscopy (EDXS). The data for the bioengineered htAbs constructed of: anti-SSEA-4, anti-TRA-1-60, anti-myosin, anti-actinin are presented in these graphs. (a) The measurements for each patient were conducted in triplicates. The data presented here are representative to all the samples studied. Anchoring of the patients’ human primary skin or cardiac fibroblasts (hpcF), human cultured embryonic stem cells H1, H9 (hESC), and human cultured fibroblasts IMR90 (hF) were the controls. Anchoring to the human cultured endothelial cells was the reference (hiPSC EC). Retention of the anchored hiPSCs onto the sarcomeres upon the start (hiPSC 1d) was compared with that after 24h (hiPSC 24h). For comparison the hpcF, hESC, and hF cells were measured at the start of the trial and after 12 days. (b) Specificity the htAbs to anchor the hiPSCs to sarcomeres (hiPSCs arc) was tested by blocking the antigens on the hiPSCs with non-specific tetravalent antibodies (anti-EGFRvIII, antiEGFRvIV, anti-CEA, anti-PSMA), with the monospecific antibodies against SSEA-4, SSEA-3, TRA-1-60, TRA- 1-81 (three docking sites were locked) (hiPSC ST mtAb), monovalent monoclonal antibodies against SSEA-4, SSEA-3, TRA-1-60, TRA-1-81 (hiPSC ST mAb), or by omitting the antibodies (hiPSC no Ab). (c,d) Specificity of htAbs to anchor the hiPSCs to sarcomeres (hiPSCs arc) was also tested by blocking the antigens on the human cardiac muscle sarcomeres with the non-specific tetravalent antibodies (anti-EGFRvIII, antiEGFRvIV, anti-CEA, anti-PSMA), with the monospecific antibodies against myosin, actin, actinin, titin (three docking sites were locked) (hiPSC MA mtAb), monovalent monoclonal antibodies against myosin, actin, actinin, titin (hiPSC MA mAb), or by omitting the antibodies (hiPSC no Ab). The statistical significance was accepted for p < 0.003.